Last reviewed · How we verify
SCI -110
At a glance
| Generic name | SCI -110 |
|---|---|
| Also known as | Dronabinol and PEA |
| Sponsor | The Israeli Medical Center for Alzheimer's |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury (NA)
- The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI) (NA)
- Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI) (NA)
- SCI-110 for Alzheimer Disease and Agitation (PHASE2)
- Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCI -110 CI brief — competitive landscape report
- SCI -110 updates RSS · CI watch RSS
- The Israeli Medical Center for Alzheimer's portfolio CI